These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25750558)

  • 1. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B.
    Chon YE; Kim SU; Lee CK; Heo J; Kim JK; Yoon KT; Cho M; Lee KS; Kim DH; Choi EH; Park JY; Kim DY; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2011; 16(4):469-77. PubMed ID: 21685534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy.
    Chen CH; Hu TH; Hung CH; Wang JH; Lu SN; Lee CM
    J Viral Hepat; 2014 Aug; 21(8):e55-64. PubMed ID: 24766327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
    Ko SY; Choe WH; Kwon SY; Kim JH; Seo JW; Kim KH; Lee CH
    Scand J Gastroenterol; 2012 Nov; 47(11):1362-7. PubMed ID: 22934534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.
    Aljumah AA; Bin Selayem NA; Al-Howti SY; Dafallah M; AlGhamdi H; Mokhtar H; Albekairy AM; Sanai FM
    J Infect Chemother; 2019 Jan; 25(1):12-16. PubMed ID: 30366861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
    Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
    J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.
    Zoutendijk R; Reijnders JG; Brown A; Zoulim F; Mutimer D; Deterding K; Petersen J; Hofmann WP; Buti M; Santantonio T; van Bömmel F; Pradat P; Oo Y; Luetgehetmann M; Berg T; Hansen BE; Wedemeyer H; Janssen HL;
    Hepatology; 2011 Aug; 54(2):443-51. PubMed ID: 21563196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B.
    Park JH; Ahn SJ; Cho HJ; Kim SS; Cheong JY; Cho SW
    J Med Virol; 2016 Feb; 88(2):252-9. PubMed ID: 26178822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.